A Pilot Study of Blinatumomab in Combination With a PD1 Inhibitor, Pembrolizumab, in Pediatric and Young Adult Patients With Relapsed/Refractory CD19 Positive B-cell Acute Leukemia or Lymphoma
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Leukaemia; Lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 01 Oct 2018 Status changed from not yet recruiting to recruiting.
- 18 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Oct 2018.
- 03 Aug 2018 New trial record